Specify a stock or a cryptocurrency in the search bar to get a summary
Monopar Therapeutics Inc
MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. Address: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091
Analytics
WallStreet Target Price
18 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MNPR
Dividend Analytics MNPR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MNPR
Stock Valuation MNPR
Financials MNPR
Results | 2019 | Dynamics |